Skip to main content
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1994;3(7):S31–S33. doi: 10.1155/S0962935194000724

Targeting Drug Delivery to the Lungs by Inhalation

C O'Callaghan 1
PMCID: PMC2365599  PMID: 18475601

Abstract

Most drugs targeted to the respiratory tract are used for their local action. For example, ephidrine for nasal decongestion, beta-2 agonists for bronchodilatation, and inhaled steroids to suppress the inflammation seen in asthmatic airways. Since the drug is delivered directly to its required site, only a small quantity is needed for an adequate therapeutic response, and consequently there is a low incidence of systemic side effects compared with oral or intravenous administration. More recently, it has become apparent that the lining of the respiratory tract, from nasal mucosa to airways and alveoli, may be used for the absorption of a drug for its systemic effect. This route of administration may be particularly attractive if it avoids the metabolic destruction encountered when some drugs are administered by alternative routes (for instance, peptides and proteins are rapidly destroyed by peptidases when Oven by the oral route). If there is a lack ofclinical response to an aerosolized drug, it is important to question whether the drug has failed or whether delivery to the site of action is inadequate. To deliver therapeutic agents by inhalation to the lower respiratory tract, inhaled drug particles must have appropriate aerodynamic characteristics. In addition, the anatomy and pathophysiology of the patient's respiratory tract, mode of inhalation through the inhaler, and the characteristics of the inhalational device itself, may significantly affect drug deposition.

Full Text

The Full Text of this article is available as a PDF (304.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown P. H., Blundell G., Greening A. P., Crompton G. K. Do large volume spacer devices reduce the systemic effects of high dose inhaled corticosteroids? Thorax. 1990 Oct;45(10):736–739. doi: 10.1136/thx.45.10.736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clay M. M., Pavia D., Newman S. P., Clarke S. W. Factors influencing the size distribution of aerosols from jet nebulisers. Thorax. 1983 Oct;38(10):755–759. doi: 10.1136/thx.38.10.755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Collis G. G., Cole C. H., Le Souëf P. N. Dilution of nebulised aerosols by air entrainment in children. Lancet. 1990 Aug 11;336(8711):341–343. doi: 10.1016/0140-6736(90)91880-j. [DOI] [PubMed] [Google Scholar]
  4. Everard M. L., Clark A. R., Milner A. D. Drug delivery from jet nebulisers. Arch Dis Child. 1992 May;67(5):586–591. doi: 10.1136/adc.67.5.586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. O'Callaghan C., Cant M., Robertson C. Delivery of beclomethasone dipropionate from a spacer device: what dose is available for inhalation? Thorax. 1994 Oct;49(10):961–964. doi: 10.1136/thx.49.10.961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. O'Callaghan C., Lynch J., Cant M., Robertson C. Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuations of drug. Thorax. 1993 Jun;48(6):603–606. doi: 10.1136/thx.48.6.603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Prahl P., Jensen T. Decreased adreno-cortical suppression utilizing the Nebuhaler for inhalation of steroid aerosols. Clin Allergy. 1987 Sep;17(5):393–398. doi: 10.1111/j.1365-2222.1987.tb02031.x. [DOI] [PubMed] [Google Scholar]
  8. Sabin A. B., Flores Arechiga A., Fernández de Castro J., Sever J. L., Madden D. L., Shekarchi I., Albrecht P. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. JAMA. 1983 May 20;249(19):2651–2662. [PubMed] [Google Scholar]
  9. Shak S., Capon D. J., Hellmiss R., Marsters S. A., Baker C. L. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9188–9192. doi: 10.1073/pnas.87.23.9188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Shanley D. J., Luyckx B. A., Haggerty M. F., Murphy T. F. Spontaneous pneumothorax in AIDS patients with recurrent Pneumocystis carinii pneumonia despite aerosolized pentamidine prophylaxis. Chest. 1991 Feb;99(2):502–504. doi: 10.1378/chest.99.2.502. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES